Do you suffer from acid reflux?
Are you taking a PPI medication?
Do you still have symptoms or are you troubled with night time reflux?

➡️ Click HERE to Book a Consultation: https://rootcausemedicalclinics.com/locations/telemedicine/
Call us directly: 727-335-0400

There is a new antacid drug on the market called Vonoprazan. It was created in Japan where they have been using it for 10 years. Here in the U.S. it's been on the market for just a few years - 2022 and 2023. It was approved for patients with an H. pylori infection and those with erosive esophagitis respectively. It is also utilized for those patients who are non-responders to a PPI.

Pros: it's stronger, lasts longer and acts faster than PPIs. And it seems to be more effective for H. pylori infections and erosive esophagitis.

Cons: it's more expensive, insurance may not cover it, and it suffers many of the same side effects as PPIs. Chief amongst them is shifting your microbiome to favor "bad bacteria" grwoth which in fact sets you up to continue to have acid reflux. 

Further it reduces beneficial bacteria that can create obesity, hiatal hernia, and chronic reflux.

In addition, it increases your risk for C. diff infections, a dangerous form of diarrhea that can be life-threatening, causes bloat, nausea, loss of taste, headaches, fluid retention, kidney injury and skin rashes, along with osteoporosis, deficiency of vitamin B12, calcium and magnesium.

To determine what most makes sense for you, find a clinician who understands the drug options, side effects, along with natural options for treatment. As an example, H. pylori can be treated naturally very effectively. 

Finding a clinician who can help address the root cause of acid reflux could lessen the duration either antacid drug.

If you'd like help we're here for you. The best next step is to contact us for a consultation and then we can determine if what we do is a good fit for you. Call 727-335-0400.


References:
1. Kato M, Suzuki M, Nagahara A, et al. "Vonoprazan Versus Lansoprazole for Healing and Maintenance of Erosive Esophagitis", 2022, Gastroenterology

2. Hori K, Matsukawa J, Umeno M, et al. "Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan" 2020, Gut

3. Take S, Mizuno M, Ishiki K, et al. "Eradication efficacy and the effect of vonoprazan–amoxicillin dual therapy" 2025, The Lancet Microbe

4. Wang X, Chen Y, Li X, et al. "Effect of Potassium-Competitive Acid Blockers on Human Gut Microbiota: A Systematic Review and Meta-analysis" 2023, Frontiers in Pharmacology

5. Takayuki Taketo, et al. "Long-term potassium-competitive acid blockers administration changes gut microbiota: insights from a 2.2-year cohort study" 2023, Helicobacter

6. Sugimoto T, Takahashi S, et al. "Gut microbiota changes related to Helicobacter pylori eradication with vonoprazan containing triple therapy among adolescents: a prospective multicenter study" 2020, Scientific Reports

#guthealth #hiatalhernia #rootcausemedicine 

Disclaimer: The information provided in this video is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of your physician or other qualified health provider with any questions you may have regarding your health, medical condition, or treatment options. Never disregard professional medical advice or delay in seeking it because of something you have seen or heard in this video.
The views expressed are based on my clinical experience and current scientific understanding as of the date of publication. Individual results may vary.